🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us to learn all things #LCSM at the #OncoAlertColloquium today Great to learn from experts gilberto lopes Charu Aggarwal, MD, MPH, FASCO Biagio Ricciuti, MD PhD Umberto Malapelle Henning Willers, MD, FASTRO Maryam Lustberg MD, MPH, FASCO #PauloBossi #HannahWardil Beaumont RCSI Cancer Centre RCSI Research and Innovation Beaumont Hospital OncoAlert

Day Two #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 buff.ly/3Eym4P4 Charu Aggarwal, MD, MPH, FASCO 🇺🇸 of Penn Medicine Covering Advanced #NSCLC 🫁 Non Small Cell #LungCancer in Review REGISTER NOW for a Live chat with Dr. Aggarwal This set of abstracts for discussion highlights

Day Two #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 buff.ly/4hxLWZQ Henning Willers, MD, FASTRO & Katie Keane 🇺🇸 of Mass General Cancer Center Covering #LungCancer 🫁 Radiotherapy: Year in Review REGISTER NOW for a Live chat with Drs. Keane and Willers Consolidation osimertinib

BBO-8520: First-In-Class dual inhibitor of KRAS G12Ci in both GTP-Bound (ON) + GDP-Bound (OFF) states. Cancer Discovery ✅binds in the Switch-II/Helix3 pocket ✅rapid target engagement in vivo 📉tumor regression observed in multiple models, including those resistant to KRASG12C(OFF).

#TTLC “Best of Oral Abstracts” from a rising star Kelsey Pan, MD, MPH Biagio Ricciuti, MD PhD IASLC Eric K. Singhi, MD MD Anderson Cancer Center 👉 We assembled the largest international cohort of LMD #lungcancer (592 pts) #LMD #lungcancer. We investigated: (1) What is the LMD overall survival (LM-OS) for

#TTLC25 "Best of Oral ABstracts" Biagio Ricciuti, MD PhD Eric K. Singhi, MD 👉 Dr. Federica Pecci’s #METex14 NSCLC project although no overall difference in PFS starting with either ICI or TKI, BUT: (1) High PDL1 pts benefit more from first-line ICI more. (2) Low PDL1 and CNS mets pts

Proud of Federica Pecci for her amazing talk at #TTLC25 on our collaborative study comparing #MET TKIs vs #ICI for pts w/ METex14 #NSCLC. Co-led w/ ✨Xiuning Le MD PhD ✨this work provides key insights for personalized tx strategies for MET+ NSCLC. MD Anderson Cancer Center & Dana-Farber News.

Join us for the final #TTLC25 symposium at 1pm today where we’ll discuss rw scenarios and share insights on optimizing treatment for our pts with unresectable stage III & metastatic #NSCLC PER W/ Marina Garassino & #SarahGoldberg Online registration:event.gotoper.com/event/8241f134…

Amazing post #TTLC25 IASLC sunset conversations with dearest comrade Biagio Ricciuti, MD PhD , brilliant clinician scientist, on how family and friends are what matter the most! Missing Don Alessio Cortellini . Lateral mentorship as coined by Heather Wakelee at its best !

Check out the latest Oncology HERE & NOW Webcast/Podcast! 🎧 Join @oncoalert’s Faulty🚨 Elisa Agostinetto 🇧🇪 & Maryam Lustberg MD, MPH, FASCO 🇺🇸 as they explore the role of adj CDK 4/6 inhibitors in #BreastCancer, and more. Listen now: 👉 Buzzsprout: buzzsprout.com/1324033/episod… 👉 Apple

The 🚨OncoAlert🚨Newsletter Covering March 14-20, 2025 is out! REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week updates include: ✅Fertility Preservation Guidelines ASCO ✅ #ADAURA 🫁 & MRD in #NSCLC ✅ #POLAR ❄️ in #breastcancer ✅Adj

Engaging discussion on the potential role of ctDNA/MRD in early-stage #NSCLC at #OKTO25. While these biomarkers show promise for early detection and treatment monitoring, they are not yet validated for routine clinical use. Rafeh Naqash, MD Amin Nassar, MD Bruna Pellini, MD OncoAlert

Fantastic wrap up Binaytara #okto25 with an awesome line up of speakers/ faculty! Bruna Pellini, MD Sonam Puri MD Biagio Ricciuti, MD PhD Fawzi Abu Rous, MD Eric K. Singhi, MD Tejas Patil Firas Jafri Kaushal Parikh Asrar AlAhmadi, MD, MAS-CR - أسرار الأحمدي Naoko Takebe Maida Hafiz and others. Thank you everyone for attending :)

Don’t miss the weekly OncoAlert🚨 Round Up (March 20-27) REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week including: ✅Averted #LungCancer 🫁 deaths due to reductions in cigarette smoking🚬 in the United States🇺🇸 1970–2022 acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

The OncoAlert 🚨 VJ Oncology Journal Club LITESPARK-005 out on Lancet Oncology : thelancet.com/journals/lanon… A Great Pleasure to have Brian Rini, MD 🇺🇸& Tom Powles 🇬🇧of Uromigos discussing LITESPARK-005 : #Health-related quality of life with #belzutifan 🆚 #everolimus for advanced

#MET kinase domain mutations can drive off-target resistance to targeted therapies in #NSCLC. In this study led by #ShesiruNakazawa & Federica Pecci, we demonstrate how combinations w/ MET TKI can overcome this resistance. JTO & JTO CRR OncoAlert IASLC jto.org/article/S1556-…

The FDA 🇺🇸approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR #ColorectalCancer fda.gov/drugs/resource… FDA approves combination of nivolumab and ipilimumab for adults and pediatric patients aged 12 and older with unresectable or metastatic

Integrated analysis of TRUST I&II ph2 trials of taletrectinib in #ROS1+ #NSCLC. ✅ TKI-naïve: ORR 88.8%, mDOR 44.2 mo, mPFS 45.6 mo ✅ TKI-pretreated: cORR 55.8%, mDOR 16.6 mo, mPFS 9.7 mo 🧬 G2032R: cORR 61.5% ascopubs.org/doi/10.1200/JC… OncoAlert Journal of Clinical Oncology #LCSM

The OncoAlert 🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week discussing (among others): ✅Assessment of a Polygenic Risk Score in Screening for #ProstateCancer (BARCODE1)

Don’t miss the new OncoAlert🚨Newsletter Covering April 11-17, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅SBRT☢️ & IO in #KidneyCancer ✅ Challenges in #SCLC heterogeneity &Plasticity🫁